GET DAILY SIGNALSBeam Therapeutics (BEAM) Reports Wider Q3 Loss: Pipeline Progress Remains Key
Key Takeaways
- Beam Therapeutics reported a third-quarter 2026 net loss of $134.4 million, or $1.28 per share, wider than the $112.6 million loss ($1.10 per share) a year earlier.
- License and collaboration revenue fell to roughly $307,000 from $9.7 million a year ago, well below the consensus estimate of around $8.75 million.
- Research and development (R&D) expenses were essentially flat at $110.1 million, while general and administrative (G&A) expenses rose about 17.9% to $31.5 million.
- The company held $1.0 billion in cash, cash equivalents, and marketable securities as of September 30, 2026, with runway projected into mid-2029.
- Pipeline momentum remained the central focus, with a potential Biologics License Application (BLA) for risto-cel targeted as early as year-end 2026.
Why the Earnings Context Matters
Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using base editing, a gene-editing technique designed to make precise, single-letter DNA changes without cutting both strands of the genome. Because it has no approved products yet, its quarterly results are driven less by revenue than by clinical execution, cash runway, and spending discipline. The third-quarter update carried extra weight because the company is approaching a potential first regulatory filing for risto-cel in sickle cell disease (SCD) while advancing multiple other programs, including BEAM-302 for alpha-1 antitrypsin deficiency (AATD). For investors, the report was a checkpoint on whether Beam can fund its growing pipeline through key value-inflection milestones without near-term dilution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
For the third quarter ended September 30, 2026, Beam Therapeutics reported a net loss of $134.4 million, or $1.28 per share, compared with a net loss of $112.6 million, or $1.10 per share, in the prior-year period. The result was wider than the consensus estimate of a loss of roughly $1.15 per share. License and collaboration revenue came in at about $307,000, down sharply from $9.7 million a year earlier and below analyst expectations near $8.75 million, reflecting the lumpy, milestone-driven nature of collaboration income for a company without approved products.
R&D expenses held nearly flat at $110.1 million versus $109.8 million, while G&A expenses increased to $31.5 million from $26.7 million as Beam builds out its commercial organization. The company ended the quarter with $1.0 billion in cash, cash equivalents, and marketable securities, down from $1.2 billion at the end of 2025, and expects this balance, together with an additional $200 million to be drawn from its Sixth Street facility, to fund operations into mid-2029.
Market Reaction and Investor Sentiment
BEAM shares came under pressure in the session following the release, as the wider-than-expected quarterly loss and the sizable revenue shortfall weighed on sentiment. For a clinical-stage biotech, however, quarterly revenue misses tied to collaboration milestone timing carry less informational weight than pipeline and cash-position updates. Investor attention quickly shifted to the clinical narrative: the company reiterated plans to report updated risto-cel data and submit a U.S. BLA as early as year-end 2026, and to complete dosing in the pivotal BEAM-302 cohort in the first half of 2027. The multi-year cash runway also helped temper concerns about near-term dilution, even as rising G&A spending signaled investment in a future commercial launch.
Forward Outlook and Key Factors to Monitor
The most closely watched near-term catalyst is the potential BLA submission for risto-cel in sickle cell disease, targeted for as early as the end of 2026. Investors will be watching for updated clinical data and any signals from the U.S. Food and Drug Administration (FDA) about the regulatory path forward.
Beyond risto-cel, the BEAM-302 program for AATD remains a key focus. Updated Phase 1/2 data presented in September 2026 showed durable increases in functional AAT and reductions in mutant Z-AAT with up to 18 months of follow-up, and completion of dosing in the global pivotal cohort is expected in the first half of 2027.
Early BEAM-301 data in glycogen storage disease type Ia showed dose-dependent improvements in time to fasting hypoglycemia, and Beam is now enrolling a higher 60 mg cohort while planning FDA engagement. Meanwhile, dosing in the Phase 1/2 trial of BEAM-304 for phenylketonuria (PKU) is anticipated to begin in early 2027.
Financially, investors should monitor how quickly the $1.0 billion cash balance is deployed across four advancing programs, whether the Sixth Street drawdown conditions are met, and how G&A costs trend as the company builds toward a potential commercial launch. Clinical or regulatory delays, as well as shifts in the competitive genetic-medicine landscape, remain among the primary risks to watch.
Using AI Tools in My Research Process
One tool I frequently turn to for deeper analysis is Tickeron’s AI Screener. It allows me to quickly filter biotech names by technical patterns, fundamentals, and AI-driven signals, helping refine watchlists without manual effort. This has proven useful when evaluating companies like BEAM alongside peers during earnings season.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BEAM saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for BEAM moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In 52 of the 56 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BEAM moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
BEAM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BEAM as a result. In 68 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on September 29, 2026. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.
BEAM moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +15.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 197 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.548) is normal, around the industry mean (3.104). P/E Ratio (-38.159) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.
Industry Biotechnology
Advertisement